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The cellular REDOX regulatory systems play a central role in maintaining REDOX homeostasis that is crucial for cell integrity,
survival, and proliferation. To date, a substantial amount of data has demonstrated that cancer cells typically undergo increasing
oxidative stress as the tumor develops, upregulating these important antioxidant systems in order to survive, proliferate, and
metastasize under these extreme oxidative stress conditions. Since a large number of chemotherapeutic agents currently used in the
clinic rely on the induction of ROS overload or change of ROS quality to kill the tumor, the cancer cell REDOXadaptation represents
a significant obstacle to conventional chemotherapy. In this review we will first examine the different factors that contribute to the
enhanced oxidative stress generally observed within the tumormicroenvironment.We will thenmake a comprehensive assessment
of the current literature regarding the main antioxidant proteins and systems that have been shown to be positively associated with
tumor progression and chemoresistance. Finally we will make an analysis of commonly used chemotherapeutic drugs that induce
ROS.The current knowledge of cancer cell REDOX adaptation raises the issue of developing novel and more effective therapies for
these tumors that are usually resistant to conventional ROS inducing chemotherapy.
1. Introduction
Reactive oxygen species (ROS) are radical and nonradical
oxygen-containing chemical molecules that show different
degrees of reactivity. ROS include biologically important
molecules such as superoxide anion (O
2
∙−), hydroxyl radical
(∙OH) and hydrogen peroxide (H
2
O
2
). For a long time ROS
have been tagged as harmful oxidants; however it is currently
well established that the ROS molecule H
2
O
2
constitutes an
important second messenger in cell signaling transduction.
This is due to its high diffusion rate across membranes partic-
ularly through the use of aquaporins and its ability to target
reactive/REDOX sensitive cysteine residues in proteins [1–6].
Activation of NADPH oxidases (NOX) through the binding
of growth factors, cytokines, neurotransmitters, and hor-
mones to their receptors leads to the inducible production of
O
2
∙− that is subsequently converted intoH
2
O
2
, by the enzyme
superoxide dismutase (SOD). To date, H
2
O
2
-dependent sig-
naling has been shown to play a key role in the regulation of
many cellular processes including differentiation, prolifera-
tion, migration, and apoptosis [3, 7–9]. Due to their reactive
properties these species contribute, on different levels, to
protein oxidation, lipid peroxidation, and/or DNA damage
that can ultimately result in cell death or tumorigenesis (in
case of DNA mutagenesis) [10, 11]. Consequently cells have
several antioxidant systems to inactivate ROS and to recycle
oxidized molecules; these include catalase, SOD, glutathione
peroxidases, and thioredoxin peroxidases. The main cellu-
lar antioxidant systems responsible for recycling REDOX
sensitive proteins are the thioredoxin (Trx) and glutathione
(GSH) systems that reduce active cysteine residues present
in ROS scavenging proteins (reestablishing their antioxidant
function) and other proteins, whose functions are regulated
by the oxidative status of key reactive cysteine residues
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Figure 1: The cellular antioxidant systems. Tumor progression
induces increasing oxidative stress. Cells have several antioxidant
systems to directly inactivate ROS (e.g., Trx peroxidases, GSH
peroxidases, catalase, and SOD) as well as REDOX regulatory sys-
tems that recycle/reactivate the ROS scavenging proteins and other
REDOX sensitive proteins (e.g., PTPs, PTEN, and transcription
factors).
(e.g., protein tyrosine phosphatases (PTPs), transcription
factors, and the phosphatase and tensin homolog, PTEN)
(Figure 1).
Several studies have shown an important role for ROS
in tumor development [12, 13]. Cancer cells generally dis-
play elevated ROS compared to normal counterparts that
give them a proliferative advantage and promote malignant
progression [14]. In the tumor site the hypoxic cancer cells
(in a low oxygen environment) typically show even higher
levels of ROS compared to nonhypoxic cancer cells [15].
To deal with the increasing oxidative stress experienced as
the tumor progresses, cancer cells upregulate the cellular
antioxidant systems. This allows the cancer cells to maintain
low to moderate levels of ROS (important for the activation
of proliferative signaling pathways) while avoiding high levels
of ROS that have damaging effects and can induce cell death
[16–18].
A large number of currently used chemotherapeutic
agents kill cancer cells in part through the generation of ROS.
These drugs are less toxic to normal cells that have lower
endogenous levels of ROS. Consequently, the upregulation of
antioxidant proteins within the cancer cells will render them
more resistant to chemotherapy [17–20].
In this reviewwewill make a comprehensive examination
of the current literature regarding the redox regulatory sys-
tems that become upregulated in cancer and their role in pro-
moting tumor progression and resistance to chemotherapy. A
better understanding of the molecular mechanisms used by
cancer cells to adapt and survive to oxidative stress may also
allow the development of more efficient chemotherapeutic
treatments.
2. Sources of ROS in Cancer
The existing high levels of ROS typically observed in cancer
cells are the result of accumulation of intrinsic and/or
environmental factors.
2.1. Intrinsic Sources of ROS. Several factors within the
tumor site contribute to the generation of high levels of
ROS in the cancer cells. The more relevant factors include
hypoxia (low levels of oxygen), enhanced cellular metabolic
activity, mitochondrial dysfunction, increased growth factor
receptor mediated signaling transduction, oncogene activ-
ity, increased activity of oxidases, lipoxygenases, cyclooxy-
genases and thymidine phosphorylase, and the crosstalk
between cancer cells and immune cells recruited to the tumor
site (Figure 2) [21, 22].
Within the tumor mass, it has been well established that
hypoxic cancer cells generally have higher levels of ROS
compared to nonhypoxic counterparts. Hypoxia contributes
to the production of ROS through different mechanisms.The
major regulator of the hypoxic response is the transcription
factor Hypoxia Inducible Factor (HIF). The regulation of
the alpha subunit of this transcription factor (HIF-𝛼) is
dependent on intracellular levels of oxygen. HIF-𝛼 regulation
is mediated by the action of prolyl hydroxylases (PHDs),
enzymes that in the presence of normal concentrations of
oxygen (normoxia) are able to hydroxylate HIF-𝛼 at two
prolyl residues allowing the binding of the protein von
Hippel-Lindau (pVHL). VHL in its turn recruits E3 ubiquitin
ligases which target HIF-1𝛼 for proteasomal degradation [23–
25]. Low levels of oxygen lead to the inhibition of PHDs
and subsequent stabilization and accumulation of the HIF-
𝛼 subunit. HIF-𝛼 translocates to the nucleus and binds
to the HIF-1𝛽 subunit and cofactors such as CBP/p300
inducing the transcription of more than one hundred genes
involved in promoting angiogenesis (formation of new blood
vessels from preexisting blood vessels), glycolysis, epithelial-
mesenchymal transition (EMT), proliferation, invasion, and
recruitment of inflammatory cells to the tumor site [26, 27].
Hypoxia induced glycolysis and subsequent inhibition
of oxidative phosphorylation at the mitochondrial mem-
brane leads to an increase in ROS levels mediated by the
mitochondrial complex III [28–30]. The hypoxic response
also promotes the elevation of intracellular ROS via HIF
dependent transcriptional activation of genes that encode for
growth factors and their receptors. Binding of these growth
factors to their receptors at the surface of cancer cells triggers
signaling pathways that induce the activation of NADPH
oxidases (NOX). NOX are responsible for the production of
O
2
∙−, which is then converted into H
2
O
2
.
HIF-1𝛼 and HIF-2𝛼 stabilization are also dependent on
ROS. Gao et al. showed for the first time a decrease in tumor
growth inmice treated with the antioxidant N-acetyl cysteine
(NAC) that was traced to a redox mediated reduction in the
levels of HIF [31]. In this way ROS is not only a by-product
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Figure 2: Sources of ROS in cancer. A number of intrinsic and extrinsic factors contribute to oxidative stress within the tumor as illustrated
in the figure.
of hypoxia, but it also contributes to the hypoxic response
by stabilizing its main regulator and thus creating a positive
feedback loop. A number of studies have shown that the
ROS produced in the mitochondria during hypoxia promote
the oxidation/inactivation of prolyl hydroxylases (PHDs)
thus stabilizing HIF-1𝛼 and HIF-2𝛼 [30, 32]. Furthermore
the enhanced activation of NOX observed during hypoxia
promotes NF-k𝛽 dependent HIF-1𝛼 transcription [33].
In cancer cells (as in normal cells), the mitochondria is
thought to be the largest contributor to intracellular ROS that
are generated as by-products of oxidative phosphorylation.
The mitochondrial electron transport chain is composed of
complexes I–IV and ATP synthase in the inner mitochon-
drial membrane. Complexes I and II oxidize NADH and
FADH2, respectively, and transfer the resulting electrons to
ubiquinol, which carries it to complex III. Within complex
III the electrons are shuttled across the inner mitochondrial
membrane to cytochrome c, which carries them to complex
IV. The flow of electrons throughout the respiratory chain
culminates at complex IV with the reduction of molecular
oxygen to water. The incremental release of energy resulting
from electron transfer is used to pump protons (hydrogen
ions) into the intermembrane space generating a proton
gradient, the dissipation of which is used by ATP synthase,
to power the phosphorylation of ADP to ATP. Throughout
this process, a small percentage of molecular oxygen can also
undergo a one-electron reduction generating O
2
∙− [27, 34].
O
2
∙− is produced in complexes I and III of the electron
transport chain and released to the intermembrane space
(approximately 80%) or to themitochondrialmatrix (approx-
imately 20%) [35, 36]. O
2
∙− can be converted into H
2
O
2
that is able to cross the membranes and translocate to the
cytoplasm and subsequently into the nucleus [1, 2]. In these
different cellular compartments H
2
O
2
can oxidize several
cellular components, including proteins, lipids, and DNA (in
the nucleus and mitochondria). Although peroxisomes are
cellular organelles that are involved in ROS scavenging (via
catalase mediated conversion of H
2
O
2
into O
2
and H
2
O)
they also contribute to intracellular ROS production through
the 𝛽-oxidation of fatty acids and by flavin oxidase activity
[37]. The endoplasmic reticulum (ER) also contributes to the
elevation of intracellular ROS levels via protein oxidation
(disulphide bond formation) that occurs during the process
of protein folding [38].
NOX constitute another important source of ROS in
cancer cells. The NOX family consists of seven members,
namely, NOX 1–5 and the dual oxidases DUOX 1-2. NOX are
composed of transmembrane and cytoplasmic subunits that
exert distinct functions (regulatory/catalytic). The catalytic
subunit of all NOX isoforms contains six transmembrane
domains in the N-terminal half, four conserved histidine
residues located in the third and fifth transmembrane helices
which coordinate two hemes, and a flavoprotein and an
NADPH-binding domain in the cytosolic C-terminal region
[39]. The NOX catalytic subunit transfers an electron from
intracellular NADPH across the cytoplasmic membrane to
oxygen via FAD and the two heme groups, with the second
heme group being responsible for reducing extracellular
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molecular oxygen to produce O
2
∙−. The O
2
∙− can be rapidly
converted into H
2
O
2
either spontaneously or through the
action of SOD, which crosses the plasma membrane into
the cytoplasm [39]. NOX are activated by various signaling
proteins, including growth factors, cytokines, hormones, and
neurotransmitters that are typically overexpressed within the
tumor microenvironment leading to exacerbated activation
of NOX and consequently increased levels of ROS within the
cancer cells [3, 8].
Nowadays, it is well established that, in addition to
the cancer cells, the tumor mass is constituted by innate
immune cells (including macrophages, neutrophils, mast
cells, myeloid-derived suppressor cells, dendritic cells, and
natural killer cells); adaptive immune cells (T and B lym-
phocytes); and cells from the surrounding stroma that
are recruited to the tumor site (consisting of fibroblasts,
endothelial cells, and pericytes) [40]. These noncancerous
cells constitute the tumor microenvironment and play a key
role in tumorigenesis. Tumor associated cells are capable
of inducing the generation of ROS in cancer cells through
the secretion of various growth factors and other signaling
proteins leading to the activation of NOX in the cancer
cell. Neutrophils and macrophages can produce a rapid
burst of O
2
∙− (primarily mediated via NOX) leading to the
subsequent generation of H
2
O
2
that can diffuse through
the cytoplasmic membrane and into the neighboring cancer
cells [35, 41]. Tumor associated macrophages (TAMs) can
also produce nitric oxide within the tumor site through the
activation of nitric oxide synthase 2 (NOX2). Nitric oxide
reacts with superoxide to produce peroxynitrite (ONOO-)
that can either be protonated to peroxynitrous acid and then
spontaneously decompose into nitrogen dioxide (NO
2
) and
∙OH (highly reactive/oxidizing) or react with carbon diox-
ide (CO
2
), yielding nitrosoperoxy carboxylate (ONOOCO
2
)
which decomposes into carbonate radicals (CO
3
∙−) and NO
2
[42, 43].
2.2. Environmental Sources of ROS. Environmental sources
of ROS can also significantly contribute to tumorigenesis.
Ionizing radiation is the most studied source of environmen-
tal ROS and has been shown to play a role in all stages of
carcinogenesis from cancer initiation to tumor progression.
Ionizing radiation generates ROS through the radiolysis of
water molecules and also by secondary reactions that can
persist and diffuse within the cells [44].
Other environmental factors such as tobacco compo-
nents, xenobiotics, chlorinated compounds, metal ions, bar-
biturates, and phorbol esters can generate ROS in the cells by
metabolism to primary radical intermediates or by activating
endogenous sources of ROS (Figure 2) [45].
3. Cancer REDOX Adaptation
To balance the beneficial effects of low to moderate levels
of ROS, which induce proliferative signaling pathways, and
avoid the harmful oxidant effects of high levels of ROS that
can damage proteins, lipids, and DNA, cancer cells undergo
REDOX adaptation. Increasing evidence has demonstrated a
crucial role for the cellular antioxidant systems in supporting
tumor initiation, progression, and chemoresistance. Bellow
we summarize what is currently known regarding the main
antioxidant proteins/systems involved in cancer (Figure 3).
3.1. GSH System. The GSH and Trx systems are the main
antioxidant systems responsible for the reduction of redox
sensitive proteins in the cells.
The tripeptide GSH is the most abundant nonenzymatic
antioxidant in the cell. GSH is a multifunctional antioxidant
being able to (i) function as a cofactor of several oxida-
tive stress detoxifying enzymes, for example, glutathione
peroxidase (GPx), glutathione transferase, and others; (ii)
directly scavenge ROS, such as hydroxyl radical and singlet
oxygen; (iii) detoxify hydrogen peroxide and lipid peroxides
through the catalytic activity of glutathione peroxidase; (iv)
regenerate/reduce vitamins C and E; and (v) react with
oxidized sulphenic acid and thiyl radical groups in proteins to
form S-glutathionylated proteins (protein-SSG), protecting
these proteins from further oxidation. S-Glutathionylated
proteins can then be further reduced by the glutathione
cycle through the action of glutathione reductase and small
proteins such as glutaredoxin and thioredoxin [46–48].
It is well known that GSH metabolism is modified in
a vast number of cancers. High levels of GSH have been
reported inmany types of cancer including breast,melanoma,
and liver. Furthermore a direct correlation between GSH
concentration and cellular proliferation and metastasis has
also been established [18, 47, 49]. It is important to keep
in mind that the GSH system has many components and
that a slight alteration in one of them may have an instant
result, disrupting the balance of cellular antioxidant response
and REDOX homeostasis. Various modifications within the
GSH system have been observed in cancer: higher levels
of GSH-related enzymes, such as 𝛾-glutamylcysteine ligase
(GCL), 𝛾-glutamyl-transpeptidase (GGT), and glutathione-
S-transferases (GST), have been reported, as well as higher
expression of GSH-transporting pumps [50–52]. Decreased
GSH/GSSG ratio has also been found in advanced cancer
patients; this can be explained by an increased generation of
H
2
O
2
that readily oxidizes GSH, turning it into GSSG [48].
The GSH system is a major contributor to chemother-
apy resistance. This system participates not only in the
cellular antioxidant defense, but also in drug-resistance
metabolic processes including the detoxification and efflux
of xenobiotics. The GSH system also participates in DNA
repair processes as well as in the inactivation of the cancer
cell proapoptotic pathway [18, 51, 53, 54]. GSH is able to
directly interactwith cisplatin and trisenox, inactivating these
chemotherapeutics [55, 56]. For all these reasons, significant
effort has been engaged at depleting cellular GSH levels to
sensitize tumors to the cytotoxic effects of chemotherapeutic
drugs.
Recently, a study showed that GSH plays a crucial role in
tumor initiation [57]. Using the oncogene-induced murine
model of mammary cancer (MMTV-PyMT) it was shown
that a 75% depletion in the levels of GSH in these mice led to
the formation of fewer tumors that progressed more slowly
than those in mice with normal GSH levels [57].
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Figure 3: Antioxidant systems in cancer. Cancer cells undergo REDOX adaptation to survive and proliferate in an environment with
increasing oxidative stress. Regulation of ROS levels by the cellular antioxidant systems is crucial to maintain a proliferative and mutagenic
phenotype (associated with low/moderate levels of ROS) and avoid apoptosis or senescence (associated with high levels of ROS).
3.2. TRX System. Thioredoxins (Trx) are small proteins (with
a molecular weight of approximately 12 KDa) that repair
oxidized proteins. Trx possess a conserved Cys-Gly-Pro-Cys
redox catalytic site that is able to reduce oxidized thiols
(reactive cysteine residues) in target proteins. Trx reductases
(TrxR) recycle the oxidized Trx through the transfer of
reducing equivalents from NADPH to the oxidized catalytic
site of Trx (Trx-S
2
) reducing it to a dithiol (Trx-(SH)
2
) [9,
58]. Amongst all members of the thioredoxin system, Trx1
and TrxR1 have emerged as critical redox regulators and as
potential therapeutic targets formany types of human cancers
[59].
Trx are major protein disulphide reductases in the cell,
being able to catalyze the reduction of disulphide bonds
in proteins orders of magnitude faster than GSH [60]. Trx
are involved in multiple redox-dependent signaling path-
ways in cancer by regulating redox-sensitive transcription
factors (e.g., activator protein 1 (AP-1), NF-𝜅B, and p53);
signaling proteins (e.g., protein tyrosine phosphatases, PTPs,
and PTEN); and other antioxidant proteins involved in the
regulation of these signaling cascades (e.g., peroxiredoxins).
Reduced Trx has been shown to bind to and inhibit apoptosis
signal-regulated kinase 1 (ASK1) [61]. ASK1 activates the
c-Jun N-terminal kinase (JNK) and p38 mitogen-activated
protein kinase pathways leading to apoptosis [62, 63]. Fur-
thermore, Trx also play an important role controlling cancer
cell growth through the supply of reducing equivalents for
DNA synthesis [64].
Elevated levels of Trx have been reported in multiple
types of cancers including cervical, liver, gastric, lung, and
colorectal cancers [48, 64]. Many studies have also revealed a
positive correlation between elevated levels of Trx in human
tumors and resistance to chemotherapy [65–67]. Although a
large number of reports have established a key role for the Trx
system in cancer, a recent study seems to indicate that the Trx
system is essential for tumor progression, but not initiation,
where the GSH system plays a more prominent role [57].
3.3. SOD. Superoxide dismutase (SOD) is responsible for the
dismutation of O
2
∙− into oxygen (O
2
) and H
2
O
2
(that is less
reactive than O
2
∙−), thus providing an antioxidant defense
[47]. In humans there are three isoforms of SOD: cytosolic
Cu, Zn-SOD,mitochondrialMn-SOD, and extracellular SOD
(EC-SOD) [68]. Of these isoforms, the mitochondrial Mn-
SOD has been more associated with cancer by functioning as
a mitochondrial ROS switch.
A large number of reports demonstrated the elevation
of Mn-SOD in tumors (e.g., lung, esophageal, gastric, head
and neck, prostate, and colon) compared to matched normal
tissues and elucidated that the enhanced expression of Mn-
SOD resulted in increased cancer cell invasiveness, growth,
survival, and metastatic behavior [69–75]. Overexpression of
Mn-SOD is likely a compensatory mechanism to intrinsic
ROS stress, especially in cancer cells with mitochondrial
dysfunction and consequently increased levels of O
2
∙−. In
this situation enhanced expression of Mn-SOD might help
the cancer cell to counteract superoxide stress and thus
promote tumor progression. A potential mechanism for Mn-
SOD induced metastasis is the H
2
O
2
-dependent increase in
matrix metalloproteases expression [76, 77]. Interestingly,
other reports demonstrated low activity ofMn-SOD in awide
range of cancers including cervical, breast, prostate, lung, and
liver [78–82]. These studies also showed that overexpression
of Mn-SOD in cancer cells led to decreased proliferation,
anchorage-dependent growth, and invasiveness. However,
these tumor suppressive properties of Mn-SOD were mainly
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observed in vitro, in experimental systems where cancer cells
were artificial transfected with Mn-SOD-expressing vectors
to induce high expression of this enzyme [78, 83]. Under
these conditions, the cancer cell redox homeostasis can
be significantly disturbed, leading to inhibition of cancer
cell proliferation. However, the physiological relevance of
such tumor-suppression function of Mn-SOD is still unclear
in cancer cells in vivo. Also, Mn-SOD cancer cell growth
suppression can be modulated by diminishing the levels
of carcinogen-inducing O
2
∙− [84–86] and sensitization of
cancer cells to cell death induced by different ROS-generating
agents [87]. This dual effect of SOD acting as either a tumor
promoter or a tumor suppressor should be addressed taking
into account the nature of the ROS molecules generated in
low or high SOD expressing cancer cells. O
2
∙− (which is
elevated in tumors with low SOD activity) is a reductant
of iron, which subsequently generates ∙OH by transferring
the electron to H
2
O
2
[88]. The highly reactive ∙OH can lead
to enhanced mutagenesis via DNA oxidation. On the other
hand, increased SOD activity will lead to enhanced levels of
H
2
O
2
that oxidizes reactive cysteine residues in proteins with
high specificity, constituting an important second messenger
in a wide variety of signaling pathways that activate prolifer-
ation, invasiveness, and metastasis. Furthermore, increased
levels of O
2
∙− (associated with low levels of SOD) might be
more beneficial to cancer cells in the early stages of tumor
development where oxidative stress within the tumor mass
is still low; increased levels of H
2
O
2
(associated with high
levels of SOD) might have a more prominent role at later
stages of tumor progression, lowering unspecific damage
of cellular components, while increasing H
2
O
2
dependent
signaling pathways. However there is still a lot of work to be
done to investigate these hypotheses.
3.4. Catalase. Catalase (CAT) was originally regarded as
a monofunctional peroxisomal enzyme that efficiently cat-
alyzes the conversion of H
2
O
2
into water and O
2
. This notion
has evolved over the years and catalase is now considered a
multifunctional enzyme that exhibits not only classic catalase
activity, but also peroxidase [89, 90] and oxidase functions
[91]. Moreover, catalase activity is not limited to the degrada-
tion ofH
2
O
2
, as this enzyme also degrades peroxynitrite in an
enzymatic reaction that, similarly to its classical reactionwith
H
2
O
2
, involves the formation of compound I (CATFeIV=O∙+)
[92, 93]. In addition, compound I of catalase can oxidize
NO (CATFeIV=O∙+ + 2∙NO + H
2
O → CATFeIII + 2H+
+ 2NO
2
−) [94, 95], whereas native ferricatalase (CATFeIII)
is reversibly inhibited by NO [96]. Thus, catalase has the
potential to execute a central modulatory function at the
cross point between H
2
O
2
and NO/peroxynitrite-mediated
signaling pathways.
Decreased CAT activity has been reported in cancer [69].
This low CAT activity leads to high levels of H
2
O
2
and
creates an intracellular environment favorable to DNAmuta-
genesis and to the activation of H
2
O
2
-dependent signaling
pathways that typically trigger cell proliferation, invasion
and metastatic phenotypes, consequently promoting tumor
progression [35, 97, 98].
However, malignant cells may acquire membrane-
associated catalase. Cancer cells exhibit enhanced NOX1-
dependent superoxide anion generation [93, 99–102]. Various
studies have shown that the overexpression of membrane-
associated catalase on the outer surface of tumor cells has
a protective role against apoptosis induced intercellular
ROS signaling [93, 101–103]. Catalase-mediated protection
from intercellular ROS signaling was found in all human
cancer cell lines studied so far (more than 70 cell lines)
[104], indicating that this might be an important mechanism
for tumor survival. Efficient protection of tumor cells by
membrane-associated catalase is not in contradiction to the
finding that, in general, tumor cells have less catalase than
normal tissue, as the surface of the tumor cell with its high
local concentration of catalase represents a small proportion
of the total cellular mass [105].
3.5. Peroxiredoxins. Peroxiredoxins (Prdx) are thioredoxin
peroxidases that are divided into three classes: typical 2-
cysteine peroxiredoxins (PrxI–IV), atypical 2-cysteine perox-
iredoxins (PrxV), and 1-cysteine peroxiredoxins (PrxVI) [50].
Although their individual roles in cellular redox regulation
and antioxidant protection are distinct, they all catalyze
the reduction of H
2
O
2
, organic hydroperoxides, and per-
oxynitrite, to balance intracellular ROS levels [106, 107].
Due to their widespread distribution within the cell, Prdx
are thought to constitute broad-range cellular antioxidant
defenders. However, recent studies have demonstrated that
typical 2-cysteine peroxiredoxins (Prdx I–IV) play key cell
signaling regulatory roles by either interacting directly with
specific REDOX-sensitive signaling protein(s) or by being
located in the vicinity of REDOX-dependent signaling cas-
cades (lipid rafts) and buffering ROS generated byNOX [108].
The 2-Cys Prx have been implicated in the regulation of
diverse cellular processes, including proliferation, migration,
apoptosis, and metabolism [108].
Overexpression of all known Prdx has been reported
in many types of cancers including prostate, breast, lung,
thyroid, and mesothelioma and is associated with cancer cell
survival and tumor progression [109–112].The ROS buffering
and signaling regulatory (prosurvival) functions of Prdx have
been suggested to play a role in tumor chemoresistance [106,
107, 112–114].
3.6. APE1/Ref-1. The Apurinic/apyrimidinic endonuclease/
redox factor-1 (APE1/Ref-1) is a key enzyme that in addition
to its DNA base excision repair function it also exerts
important cellular functions in the REDOX control of mul-
tiple transcription factors involved in cancer progression,
including NF-𝜅B, STAT3, AP-1, HIF-1, and p53 [115–118].
All of these transcription factors possess reactive cysteine
residue(s) within their DNA binding domain that can be
readily oxidized/inactivated by cellular ROS. APE1/Ref-1
is able to reduce these cysteine residue(s) through the
exchange of a proton from one or two of its redox cysteine
residues (Cys65, Cys93, Cys99, or Cys138). This restores the
DNA binding capability of the transcription factors and
subsequently promotes transcription of their target genes.
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Oxidized APE1/Ref-1 is then recycled/reduced by the Trx
system [119].
APE1/Ref-1 is highly expressed in many cancers (e.g.,
breast, lung, liver, and gliomas) [120–122]. APE1/Ref-1 role
in cancer progression is likely due to its ability to increase
DNA repair and to activate antiapoptotic, inflammatory, and
growth-promoting transcription factors [121]. APE1/Ref-1 has
also been shown to be associated with tumor resistance to
both ionizing radiation and chemotherapy [123–125]. Conse-
quently, APE/Ref-1 has emerged as a promising therapeutic
target for cancer treatment [115, 120, 126].
3.7. Transcription Factors. Transcription factors can
indirectly counteract ROS in cancer. The transcription
factor nuclear factor erythroid 2-related factor 2 (NRF2)
binds to antioxidant response elements (ARE) in the
regulatory regions of target genes and induces the
transcription/expression of antioxidant enzymes [e.g.,
NAD(P)H:quinone oxidoreductase 1 (NQO1); SOD; catalase;
heme oxygenase-1 (HO-1), TrxR, GST, GSH-synthetizing
enzymes, and UDP-glucuronosyltransferases (UGTs)]
[127–129]. NRF2 is considered to be the master regulator of
intracellular antioxidant responses. NRF2 is regulated by its
binding partner KEAP1 that targets NRF2 to proteasomal
degradation [130]. It has been shown that hyperactive
and oncogenic phosphoinositide 3-kinase- (PI3K-)AKT
signaling which is commonly observed in a large number
of cancer cells activate NRF2 [46]. NRF2 mutations have
also been found in several types of tumors such as skin,
esophageal, lung, ovarian, and breast cancers [131]. Generally
these mutations are observed in the KEAP1-binding domain
of NRF2 preventing KEAP1-mediated degradation of this
transcription factor [131, 132]. Inactivating mutations in
KEAP1 have also been identified [133]. All of these mutations
lead to the constitutive stabilization of the NRF2 protein
in the nucleus, providing strong evidence for a role for
NRF2 in tumorigenesis. High expression of antioxidant
NRF2 target genes has been linked to chemoresistance.
For instance, HO-1 seems to be an important effector of
NRF-2 induced chemoresistance in myeloid leukemias and
inhibition of either NRF2 or HO-1 sensitizes the tumor to
therapy [127]. It was also described that NRF2 enhances the
cellular antioxidant capacity to counteract ROS mediated
stress in cancer cells overexpressing oncogenic KRas [20].
Forkhead box O (FOXO) transcription factors belong to
the large group of forkhead transcription factors that are all
characterized by a conserved DNA binding domain termed
the forkhead box [134]. FOXO activate the transcription
of genes that encode for antioxidant proteins, including
Mn-SOD, catalase, and sestrin 3 [135]. Although FOXO is
generally considered to be a tumor suppressor and FOXO
inactivation has been reported in a number of cancers [136,
137], recent studies have indicated that these transcription
factors might also have protumorigenic functions. It has been
shown that activated FOXO transcription factors support
the survival of Acute Myeloid Leukemia (AML) cells [138].
FOXO transcription factors are inactivated by the PI3K-
AKT pathway. Phosphorylation of FOXO by AKT leads to
FOXO translocation from the nucleus into the cytoplasm,
where they cannot exert their transcriptional function [134].
Interestingly, it has been observed that the FOXO genes are
involved in chromosomal translocations that lead to alve-
olar rhabdomyosarcoma and acute lymphoblastic leukemia
(ALL) [139]. Specifically, the paired box 3- (PAX3-) FOXO1
translocation is found in approximately 60% of all alveolar
rhabdomyosarcoma tumors [140, 141]. The PAX3-FOXO1
fusion protein is insensitive to AKT inactivation, meaning
that AKT cannot inhibit PAX-FOXO1 translocation to the
nucleus or regulate its transcriptional activity [142]. However
the contribution of FOXO transcriptional activity within the
fusion protein is still fairly unknown and increased activity of
PAX3 has been reported [141].
3.8. Dietary Antioxidant Compounds. Dietary antioxidants
are nonenzymatic compounds that, although less specific
compared to enzymatic antioxidants, appear to be important
in cellular responses to oxidative stress including during
tumorigenesis. For instance, vitamin C (ascorbic acid) is a
water-soluble antioxidant which is mostly present in the cell
in its reduced form, ascorbate, which acts as a reductant and
enzyme cofactor and directly reacts with O
2
∙−, ∙OH, and
various lipid hydroperoxides. Vitamin E (𝛼-tocopherol) is a
fat-soluble antioxidant, which acts as a free radical scavenger
by converting free radicals into tocopheryl radicals, thus low-
ering their radical damaging abilities. Selenium is a nonmetal
element that forms part of antioxidant selenoproteins such as
glutathione peroxidase and thioredoxin reductase. Vitamin
A (𝛽-carotene) is a known fat-soluble antioxidant and its
antioxidant property derives from its ability to quench singlet
oxygen and trap peroxyl radicals. Deficiency of vitamin A
causes oxidative stress, inhibiting cell repair function and
causing cell damage [46, 47].
Much debate has focused on the consumption of antioxi-
dant supplements by cancer patients undergoing chemother-
apy due to concerns that the antioxidants may interfere
with the mechanism of action of ROS generating therapeutic
agents and subsequently decrease their efficacy [143, 144].
In this way, antioxidant supplementation might help the
cancer cells to achieve redox homeostasis during tumor
progression (generally accompanied by increasing oxidative
stress). A recently published research using B-Raf and K-Ras
induced lung cancer mouse models has demonstrated that
the dietary antioxidant compound, vitamin E, can actually
promote tumor progression [145]. This study further showed
that vitamin E increased cell proliferation by decreasing ROS,
DNA damage, and p53 expression in both mouse and human
lung cancer cells [145].
Interestingly vitamin C has also been shown to have a
prooxidant function. Vitamin C can reduce catalytic metals
within the cells that in turn react with oxygen, producing
O
2
∙− that subsequently dismutates intoH
2
O
2
.Theprooxidant
function of vitamin C is observed at pharmacological doses
(millimolar concentrations). It is currently accepted that
the anticancer effect of pharmacological doses of ascorbate
is mediated by the generation of high concentrations of
extracellular H
2
O
2
that diffuses through the plasma mem-
brane causing DNA damage and triggering proapoptotic
signaling pathways which will ultimately lead to cell death
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[146, 147]. A recent study investigated the synergistic action
of pharmacological doses of vitamin C in combination with
chemotherapeutic drugs used in the clinic for the treatment
of ovarian cancer. These results showed that vitamin C
significantly increased the efficacy of carboplatin and/or
paclitaxel using a tumorigenic mouse model, where ovarian
cancer cells were intraperitoneally injected in the mice [147].
A small pilot phase 1/2a clinical trial was also conducted in
patients newly diagnosed with stage III/IV ovarian cancer
[147]. Reduction of chemotherapy-associated toxicity was
observed in patients receiving intravenous vitamin C in
addition to carboplatin and paclitaxel treatment. A tendency
for enhanced overall survival and longer time to relapse in
patients receiving vitamin C in combination with carboplatin
and paclitaxel compared to patients receiving only carbo-
platin andpaclitaxelwas observed; however these resultswere
not statistically significant. A larger clinical trial might be
useful to further clarify these results. The use of ascorbate in
cancer therapy is still a matter of debate as preclinical studies
have shown a large variation in ascorbate sensitivity even
within cancers of the same type. This may be the result of
intrinsic differences between cancer cells fromdiverse origins
(e.g., antioxidant defenses) or the tumor microenvironment
in the case of organ-specific cancers, which are presently
poorly understood. The fact that vitamin C can function
as an antioxidant (at low doses) or a prooxidant (at high
doses) is most likely at the basis of these contradictory
results and dosage as well as other factors (e.g., intrin-
sic antioxidant defenses, expression of sodium-dependent
vitamin C transporters, activation of signaling pathway(s),
etc.) should be taken into account when considering the
use of this compound in combination with ROS producing
chemotherapeutics.
3.9. Others
3.9.1. Annexin A2. Annexin A2 belongs to the family
of annexins, which are commonly described as calcium-
dependent phospholipid-binding proteins [9]. Annexin A2
is a multifunctional protein that has been shown to be
overexpressed in a large number of cancers (e.g., breast, liver,
gastric, pancreatic, lung, gliomas, colorectal, and ovarian)
and to be positively associated with metastasis and resistance
to chemotherapy [9, 148–151]. It was demonstrated that
annexin A2 is unique among the vertebrate annexins in that
it possesses an N-terminal reactive cysteine residue, Cys-8,
which is reversibly oxidized by H
2
O
2
inactivating this ROS
molecule and generating H
2
O and O
2
. Oxidized annexin
A2 is then recycled/reduced by the Trx system. Thus one
molecule of annexin A2 has the ability to degrade several
molecules of H
2
O
2
[9, 58]. The role of the antioxidant
function of annexin A2 in tumorigenesis was investigated
using a mouse animal model. This study showed that the
growth of tumors derived from annexin A2 depleted cancer
cells was significantly impaired compared to tumors derived
fromcontrol cancer cells (expressing normal levels of annexin
A2). However, the growth impairment of the annexin A2-
depleted tumors was rescued by the administration of the
antioxidant compound, N-acetyl cysteine (NAC), in the mice
during tumor formation [9, 58]. These results indicate that
annexin A2 REDOX regulatory function plays a significant
role in promoting tumor growth. It was also demonstrated
that annexin A2 depleted cancer cells were significantly more
sensitive to death induced by the ROS generating chemother-
apeutic agents, etoposide, doxorubicin, and tamoxifen [58],
elucidating for the first time a molecular mechanism by
which annexin A2 provides resistance to chemotherapy, by
functioning as an antioxidant protein. More recently it has
been shown that a fraction of cellular annexinA2 translocates
into the nucleus in response to different oxidative stress
stimuli, including X-ray radiation, Gamma-radiation, UV
radiation, etoposide, chromium VI, and H
2
O
2
[9, 152, 153].
Nuclear annexin A2 was shown to protect cellular DNA from
oxidative damage [153].
3.9.2. DJ-1. DJ-1 is a multifunctional protein that has been
shown to also have antioxidant functions. DJ-1 contains
three reactive cysteine residues, namely, Cys46, Cys53, and
Cys106, being Cys 106 the most susceptible to oxidation.
In fact, Cys 106 is essential for DJ-1 cytoprotective function
against oxidative stress and mutation of this cysteine residue
abolishes all functions of DJ-1 [154–158]. The antioxidant
functions attributed to DJ-1 include the upregulation of
intracellular glutathione synthesis via increasing glutamate
cysteine ligase enzyme [159]; inhibition of oxidative stress
induced apoptosis via direct binding of its Cys 106 residue
to ASK1 [156, 160]; stabilization of NRF2 transcription factor
that regulates the expression of many antioxidant genes (as
described above) by preventing the binding of NRF2 to its
inhibitor KEAP1 [161]. A recent study using cardiac cells
showed that DJ-1 was able to inhibit ischemia/reperfusion-
induced ROS generation, via upregulation of antioxidant
enzymes [162]. These results suggest that DJ-1 might also
trigger a similar antioxidant response in hypoxic cancer cells.
However this has not yet been investigated.
DJ-1 has been shown to be upregulated in many human
cancer types (e.g., lung, prostate, endometrial, and bladder),
which correlated with cancer cell proliferation, tumor sur-
vival, and chemoresistance [59, 163–165].
4. ROS Inducing Chemotherapy
Typically, cancer cells exhibit higher levels of endogenous
ROS compared to normal cells. For this reason a commonly
used strategy for killing cancer cells consists of using ionizing
radiation and/or chemotherapeutic drugs that induce the
generation of these oxidants to levels that are capable of
triggering apoptosis once ROS levels reach or exceed a certain
thresholdwithin the cell.The rationale for this approach relies
on the fact that since cancer cells already have high levels of
endogenous ROS prior to treatment they should reach this
apoptotic threshold faster/easier compared to normal cells
[166, 167].
Accordingly, oxidative stress has been recognized as a
tumor specific target for the design of chemotherapeutic
agents. A large number of chemotherapeutic drugs capable
of inducing oxidative stress, by interfering with various
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Table 1: Chemotherapeutic drugs commonly used in the clinic capable of inducing ROS.
Drug name Tumor type Mechanism of action for ROS induction References
Actinomycin D
Sarcomas; Wilms’ tumor; testicular;
melanoma; neuroblastoma; germ cell;
retinoblastoma; choriocarcinoma
Inhibition of Bcl-2 [179]
Bleomycin
Melanoma; Hodgkin’s and non-Hodgkin’s
lymphomas; testicular; head and neck;
cervical; malignant pleural effusions
Formation of Fe(II)-bleomycin-DNA
complex that is oxidized by O
2
[185, 187]
Busulfan Chronic myeloid leukemia GSH depletion and NOX activation [182, 183]
Carmustine Brain; Hodgkin’s and non-Hodgkin’slymphoma; melanoma; myeloma GSH depletion via inhibition of GR [169]
Cisplatin Ovarian; colon; testicular; germ cell;bladder; lung; head and neck
Increased expression of p47phox subunit
of NOX [17, 188]
DMAT Prostate Inhibition of CK2 activity [173]
Doxorubicin
Hodgkin’s and non-Hodgkin’s lymphoma;
leukemia; breast; gastric; neuroblastoma;
ovarian; lung; soft tissue and bone
sarcomas; thyroid; bladder
p53-dependent transcription of
cytochrome oxidase 2;
FOXO3-dependent transcription of Noxa
and BIM; quinone metabolism
[190]
Etoposide Lymphomas; leukemias; neuroblastoma;breast; lung; testicular; gastric
FOXO3 dependent transcription of Noxa
and BIM [188, 190]
5-Fluorouracil Gastric; colon; gynecological; breast;head and neck; lung; skin p53-dependent transcription of ROMO 1 [188, 189]
Gemcitabine Pancreatic; lung; in combination withother drugs: breast, bladder, and ovarian
Activation of AKT and ERK 1/2 which
leads to upregulation of CXCR4 [198]
Mitomycin C Colon; breast; head and neck; bladder;cervical; gastric; pancreatic; liver Inhibition of Bcl-2 [180, 202]
Paclitaxel Ovarian; breast; non-small cell lungcarcinoma; Kaposi’s sarcoma
Activation of Rac1 subunit of NOX;
disruption of the mitochondrial
membrane
[177, 178]
Tamoxifen Breast Inhibition of CK2 activity [175]
antioxidant/redox regulatory proteins and/or ROS inducing
pathways, are currently being used in the clinic (Table 1)
[168].
The chemotherapeutic agent carmustine interferes with
the GSH antioxidant system by inhibiting glutathione reduc-
tase activity. GSH is an abundant cellular antioxidant that
plays a key role in cellular REDOX homeostasis as already
described in this review. Inhibition of glutathione reductase
leads to the build-up of oxidized glutathione (GSSG) that can
no longer exert its antioxidant function; as a consequence a
significant accumulation of ROS within the cell is observed,
driving caspase-3 activation and apoptosis [166, 169, 170].
Other chemotherapeutic drugs function through ROS-
independent as well as ROS-inducing mechanisms. This is
the case for the estrogen receptor inhibitor, tamoxifen, and
for 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole
(DMAT) that inhibit the catalytic activity of protein cyclin
kinase 2 (CK2). Under normal conditions, CK2 phospho-
rylates the apoptosis repressor with caspase recruitment
domain (ARC) and Bid (proapoptotic member of the Bcl-
2 family) proteins. Phosphorylated ARC localizes to the
mitochondria, inhibiting caspase 8, while Bid phosphory-
lation by CK2 protects it from being cleaved by caspase
8. In conjunction phosphorylation of ARC and Bid by
CK2 contributes to cell survival via inhibition of apoptosis.
However, when CK2 is inhibited by tamoxifen or DMAT, it
is not able to phosphorylate neither ARC nor Bid proteins.
This will lead to caspase 8 activation, which will cleave Bid
promoting its translocation to the mitochondrial membrane
with the subsequent release of cytochrome C and activation
of additional caspases, ultimately triggering apoptosis [171–
173]. Disruption of the mitochondrial membrane by Bid will
also lead to the release of ROS into the cytosol. CK2 inhibition
also mediates NOX activation and the subsequent generation
of ROS (O
2
∙− andH
2
O
2
).This occurs because CK2 can phos-
phorylate the cytosolic subunit of NOX, p47phox, negatively
regulating NOX activity. Inhibition of CK2 by tamoxifen
or DMAT will thus enhance NOX activity and induce the
elevation of intracellular ROS which will also contribute to
cell death induced by these chemotherapeutic agents [174–
176].
Paclitaxel (also known as taxol) is another drug that is
able to enhance NOX activity. This chemotherapeutic is a
microtubule stabilizing agent that interferes with the normal
breakdown of spindle microtubules during cell division,
inhibitingmitosis and inducing apoptosis [177]. Paclitaxel has
been shown to induce the translocation of Rac1 (regulatory
subunit of NOX) from the cytosol to the plasma membrane.
The increase of Rac 1 in the plasma membrane promoted the
activation of NOX and led to the production of O
2
∙−, which
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was subsequently converted to H
2
O
2
either spontaneously or
by SOD [178]. This study showed that paclitaxel displayed a
significant cytotoxic bystander effect in neighboring cancer
cells [178], suggesting that this effect might play a substantial
role in the antitumor activity of this drug. It is noteworthy
that paclitaxel has limited ability to reach cancer cells that
are distant from the vasculature. The fact that H
2
O
2
can
diffuse reasonably far from its site of production and can
use aquaporins to enter the cells suggest that this mechanism
might contribute significantly to paclitaxel induced cancer
cytotoxicity.
The chemotherapeutic drugs actinomycin D and mito-
mycin C also activate the mitochondria-dependent apoptotic
pathway. This occurs via inactivation of the antiapoptotic
protein, Bcl-2. Bcl-2 forms heterodimers with the proapop-
totic Bcl-2 family members: Bax, Bak, Bid, BIM, PUMA, and
BAD sequestering these proteins and inhibiting apoptosis.
Inactivation of Bcl-2 by actinomycin D or mitomycin C
will elicit the release of the proapoptotic Bcl-2 family mem-
bers causing mitochondrial membrane potential collapse
and cytochrome C release from the mitochondria into the
cytosol, subsequently increasing intracellular ROS levels. In
the cytosol, cytochrome C induces apoptosis through the
activation (via cleavage) of caspase-3 and caspase-9. Excessive
ROS generation also contributes to cell death induced by
these chemotherapeutic drugs [179–181].
Awide variety ofDNAdamaging (genotoxic) chemother-
apeutic agents have been shown to induce cancer cell death in
part through the increase of intracellular ROS levels. This is
the case of busulfan, an alkylating agent that causes significant
DNA damage by promoting the crosslinking between DNA
molecules and also between DNA and proteins. Since these
crosslinks can potentially originate DNA strand breaks it
was hypothesized that busulfan most likely activates the
DNA-damage response p53 signaling pathway to induce
senescence or apoptosis. Interestingly, a p53 independent
pathway has been reported for busulfan induced senescence.
It was demonstrated that busulfan is metabolized through
conjugationwithGSH.This reaction is catalyzed byGST.This
leads to depletion of intracellular levels of GSH, followed by a
continuous increase in ROS production via NOX activation,
which in turn activate the ERK and p38 MAPK signaling
pathways, inducing cell senescence [182–184].
Bleomycin (BLM) is a chelator and a DNA damaging
agent that is known to produce single- and double-strand
breaks in the DNA as well as the release of free bases. BLM
binds to DNA via its bithiazole and N-terminal moieties
and interacts with Fe(II) via its ferrous binding site, forming
an Fe(II)-BLM-DNA complex. BLM induces an increase in
intracellular levels of ROS due to oxidation of the Fe(II)-
BLM-DNAcomplex byO
2
that leads to the generation ofO
2
∙−
and ∙OH [185–187].
Other genotoxic chemotherapeutics, such as doxorubicin
and 5-Fluorouracil, trigger a p53-dependent proapoptotic
pathway in order to kill cancer cells. The tumor suppressor
p53 is involved in the maintenance of DNA integrity and
under normal conditions it is maintained at low levels by the
E3 ubiquitin ligase MDM2. Doxorubicin and 5-fluorouracil
induce the stabilization of p53 and the subsequent
transcription of p53 regulated genes including cytochrome
oxidase 2, a component of the cellular respiratory chain that
has been shown to generate ROS [188]. Another molecular
mechanism by which 5-Fluorouracil induces the generation
of ROS is by p53-dependent transcription of the ROS
modulator 1 (ROMO1) gene. ROMO 1 protein localizes at the
mitochondrial membrane and induces mitochondrial ROS
generation [188, 189].
Doxorubicin also induces cancer cell apoptosis in a p53-
independent way. Both doxorubicin and etoposide genotoxic
chemotherapeutics promote the accumulation and nuclear
translocation of the forkhead transcription factor, FOXO3,
which activates the transcription of the proapoptotic genes
Noxa and BIM. This promotes the collapse of the mitochon-
drial membrane with the subsequent release of cytochrome
C and ROS into the cytosol ultimately inducing apopto-
sis [190–192]. Another mechanism by which doxorubicin
produces ROS involves the addition of one-electron to the
quinone moiety of doxorubicin resulting in the formation
of a semiquinone that quickly regenerates into a quinone
by reducing O
2
to O
2
∙− and H
2
O
2
. The one-electron redox
cycling of doxorubicin is accompanied by a release of iron
from intracellular stores; binding of doxorubicin with iron
results in formation of 3 : 1 drug-iron complexes that convert
O
2
∙− and H
2
O
2
into more potent ∙OH [193].
Doxorubicin is known to produce serious side effects, the
most dangerous of which being cardiomyopathy which has
been closely associated with abnormalities in mitochondrial
functions including defects in the respiratory chain/oxidative
phosphorylation system, decreased ATP production, mito-
chondrialDNAdamage,modulation ofmitochondrial sirtuin
activity, and ROS generation [193–196]. For this reason it
is important to take into account that using ROS to kill
cancer cells might also have serious consequences for the
patient that need to be taken into serious consideration before
administration of these chemotherapeutic compounds.
The chemotherapeutic drug, cisplatin, is an alkylating
agent that causesDNA crosslinking ultimately leading to p53-
dependent apoptosis. It has been shown that DNA damage
induced by cisplatin triggers a p53-dependent upregulation of
ROS that activate p38 and JNK signaling pathways inducing
apoptosis in a wide variety of cancer cell lines [188, 197].
The chemotherapeutic gemcitabine (2󸀠-2󸀠 difluorodeoxy
cytidine, dFdC) is a prodrug that is phosphorylated by
deoxycytidine kinase within the cell to form the active com-
pounds gemcitabine diphosphate (dFdCDP) and gemcitabine
triphosphate (dFdCTP). The active forms of gemcitabine
incorporate into the DNA, causing cell cycle arrest and
subsequent apoptosis [198]. It has also been shown that
gemcitabine induces ROS as an additional anticancer mecha-
nism [199]. Interestingly a report has shown that gemcitabine
induced ROS activate the proproliferative and prosurvival
MAPKS, ERK1/2, and AKT.The activation of these pathways
leads to the enhanced nuclear accumulation of NF-kB and
HIF-1𝛼 transcription factors which induce the transcription
and subsequent expression of CXCR4 protein [198, 200].
These authors also demonstrated that increased expression
of CXCR4 enhanced cancer cell invasion and migration to
CXCL12 chemokine rich environments, namely, the stroma
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and blood vessels, promoting in this way chemoresistance
due to escape from the tumor site [198]. For this reason,
ROS concentrations within the cell should be considered
during chemotherapy treatment since survival andmetastatic
mechanisms can be induced. It is crucial that ROS concen-
trations are increased until a threshold is reached where the
cellular balance is tipped to activate apoptotic pathway(s)
to stop tumor progression [176, 200]. Although high levels
of ROS induced by chemotherapeutics can have dangerous
side effects (as seen for doxorubicin), low dosages can
also promote tumor growth instead of death. It becomes
clear that finding the optimal dosage for the use of these
chemotherapeutic agents is crucial for an effective cancer
therapy.
All of the chemotherapeutics described above (summa-
rized in Table 1) generate ROS that will contribute to tumor
cell death. This is because excessive ROS can induce sig-
nificant DNA damage, protein oxidation, organelles, and/or
membranes oxidation tipping the cellular balance away from
the proliferative advantages of low/moderate ROS levels to
drive apoptosis in the presence of high ROS levels [201].
5. Conclusions and Future Directions
Increasing evidence has established that the cellular antioxi-
dant systems play a key role not only in regulating (normal)
cellular redox homeostasis, but also in protecting cancer cells
from the increasing oxidative stress that they are subjected
to during tumor progression. A large number of antioxidant
proteins have been shown to be upregulated in cancer and
to promote resistance to chemotherapy. These include not
only proteins of the GSH and Trx systems that play a
major role in recycling/reducing REDOX sensitive proteins,
whose function is regulated by oxidation/reduction of key
reactive cysteine residues, but also ROS scavenging proteins
and transcription factors that induce the cellular antioxidant
response. Novel antioxidant proteins, such as annexin A2 and
DJ-1, have also been identified more recently that contribute
significantly to tumorigenesis. In summary, since it was estab-
lished that tumors are typically under substantial oxidative
stress and as such have to adapt to survive in this extreme
environment; increasing interest has been drawn to iden-
tifying the antioxidant/redox regulatory proteins involved
in the tumor REDOX adaptation and in understanding the
molecular mechanisms by which these proteins promote
tumor progression and resistance to chemotherapy. Taking
into account that many chemotherapeutic drugs currently in
use in the clinic rely to varying degrees on ROS overload to
kill the cancer cells, the tumor REDOX adaptation presents
a major obstacle for the efficacy of these therapies. One
approach to overcome this problem could be to deplete the
cancer cell from REDOX regulatory potential through the
downregulation of antioxidant protein(s) and peptides that
have been shown to play crucial roles for tumor survival and
growth in combination with chemotherapeutics that induce
ROS.
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